Opinion|Videos|January 10, 2025
Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What, in your opinion, is the definition of the transplant-ineligible population for multiple myeloma?
- With the growing use of MRD as a biomarker, what challenges remain in standardizing its use across different treatment settings and trials?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
Fragmented Care, Financial Strain, Gender Gaps Define Life With COPD
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Primary Care Capacity Gaps Threaten Respiratory Prevention
5